Patents by Inventor Kay Alison Wardle

Kay Alison Wardle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
    Patent number: 6750195
    Abstract: A compound which acts as an antagonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: June 15, 2004
    Assignee: SmithKline Beecham Corporation p.l.c.
    Inventors: Gareth John Sanger, Kay Alison Wardle
  • Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
    Publication number: 20030045452
    Abstract: A compound which acts as an antagonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.
    Type: Application
    Filed: September 27, 2002
    Publication date: March 6, 2003
    Applicant: SmithKline Beecham PLC
    Inventors: Gareth John Sanger, Kay Alison Wardle
  • Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
    Publication number: 20020128172
    Abstract: A compound which acts as an antagonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.
    Type: Application
    Filed: October 2, 2001
    Publication date: September 12, 2002
    Applicant: SmithKline Beecham PLC
    Inventors: Gareth John Sanger, Kay Alison Wardle